- Details
- Neeraj Agarwal joins Alicia Morgans to discuss the TALAPRO-3 trial, a phase III trial for patients with metastatic hormone-sensitive prostate cancer with DNA repair gene-related alterations or homologous recombination repair gene alterations in the tumors. The trial is ongoing, and accrual is expected to be completed soon. Ultimately, the trial aims to comprehensively assess efficacy, safety, and...
|
- Details
- Kambiz Rahbar joins Alicia Morgans to discuss a post hoc analysis of the RALU study, which looks at the time interval between radium and lutetium-PSMA treatment and its effect on the safety and effectiveness of lutetium treatment in patients with metastatic castration-resistant prostate cancer. This analysis aimed to assess the safety and survival outcomes with lutetium when treatment began within...
|
- Details
- Alicia Morgans is joined by Andrew Laccetti to discuss data on the combination of enzalutamide with the next-generation antigen EPI-7386 in chemotherapy-exposed patients with castration resistance in prostate cancer (CRPC) prior to exposure to any androgen receptor (AR) pathway inhibitor. EPI-7386 represents a new approach to disrupting the androgen receptor signaling pathway, the primary driver o...
|
- Details
- Alicia Morgans is joined by Russell Pachynski to discuss EPI-7386, a first-in-class N-terminal domain androgen receptor (AR) inhibitor that suppresses androgen activity through a novel mechanism of action. Trial of this agent in a first-in-human study in heavily pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC). Dr. Pachynski provides an overview of this section of...
|
- Details
- Fred Saad joins Alicia Morgans in a discussion on the final overall survival data from the PROpel trial, a randomized controlled trial aimed to address the first-line mCRPC question in patients who have not been treated with a novel hormonal agent in the mCRPC setting. Patients were randomized to receive abiraterone and prednisone or abiraterone and olaparib. The trial's primary endpoint was radio...
|
- Details
- Michiel Van der Heijden discusses two abstracts on the use of immunotherapy in bladder cancer during his discussion with Alicia Morgans. The first abstract looked at the use of pembrolizumab in patients with non-muscle invasive bladder cancer, specifically those with high-grade TA or T1 disease that is refractory to BCG treatment. The study showed a 43% recurrence-free survival rate at one year, m...
|
- Details
- In a detailed discussion between Sam Chang and Sarah Psutka, they explore the SunRISe-4 trial, a phase II study investigating the combination of TAR-200 agent with cetrelimab in muscle invasive bladder cancer patients. The trial targets those who are due for radical cystectomy but cannot or refuse the toxic cisplatin-based neoadjuvant chemotherapy, the current standard of care. The study focuses o...
|
- Details
- Neeraj Agarwal joins Alicia Morgans to discuss the TALAPRO-2 phase 3 trial, evaluating the combination of the PARP inhibitor talazoparib and enzalutamide versus enzalutamide and placebo as first-line treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial included an all-comer population regardless of homologous recombination repair (HRR) gene mutations, and t...
|
- Details
- Cora Sternberg joins Alicia Morgans to review prostate cancer session data presented from GU ASCO 2023. Dr. Sternberg begins by discussing the ARASENS study, which explored the efficacy and safety of triplet therapy with darolutamide, chemotherapy, and ADT compared to chemotherapy and ADT alone in metastatic hormone-sensitive prostate cancer patients. The study analyzed the outcomes based on disea...
|
- Details
- Elena Castro and Alicia Morgans discuss the use of PARP inhibitors and their combinations in advanced prostate cancer. They discuss data from the TRITON3, TALAPRO-2, and PROpel studies that help to fill in gaps in the current understanding. Elena discusses the timing of PARP inhibitors versus docetaxel in HRR mutations, based on TRITON3 data. The TALAPRO-2 study showed a difference in radiographic...
|
